0001104659-22-114205.txt : 20221103 0001104659-22-114205.hdr.sgml : 20221103 20221103070838 ACCESSION NUMBER: 0001104659-22-114205 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20221103 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221103 DATE AS OF CHANGE: 20221103 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BICYCLE THERAPEUTICS plc CENTRAL INDEX KEY: 0001761612 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38916 FILM NUMBER: 221356166 BUSINESS ADDRESS: STREET 1: BLOCKS A & B, PORTWAY BUILDING STREET 2: GRANTA PARK, GREAT ABINGTON CITY: CAMBRIDGE STATE: X0 ZIP: CB21 6GS BUSINESS PHONE: 011441223261503 MAIL ADDRESS: STREET 1: BLOCKS A & B, PORTWAY BUILDING STREET 2: GRANTA PARK, GREAT ABINGTON CITY: CAMBRIDGE STATE: X0 ZIP: CB21 6GS FORMER COMPANY: FORMER CONFORMED NAME: BICYCLE THERAPEUTICS Ltd DATE OF NAME CHANGE: 20181212 8-K 1 tm2229573d1_8k.htm FORM 8-K
0001761612 false 00-0000000 true 0001761612 2022-11-03 2022-11-03 0001761612 us-gaap:CommonStockMember 2022-11-03 2022-11-03 0001761612 bcyc:AmericanDepositarySharesMember 2022-11-03 2022-11-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

November 3, 2022

Date of Report (Date of earliest event reported)

 

Bicycle Therapeutics plc

(Exact name of registrant as specified in its charter)

 

England and Wales   001-38916   Not applicable

(State or other jurisdiction of
incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

Blocks A & B, Portway Building,
Granta Park Great Abington, Cambridge
United Kingdom

CB21 6GS
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: +44 1223 261503

  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Ordinary shares, nominal value £0.01 per share n/a The Nasdaq Stock Market LLC*
American Depositary Shares, each representing one ordinary share, nominal value £0.01 per share BCYC The Nasdaq Stock Market LLC

* Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). 

Emerging growth company    ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 2.02.Results of Operations and Financial Condition

 

On November 3, 2022, Bicycle Therapeutics plc (the “Company”) issued a press release announcing financial results for the fiscal quarter ended September 30, 2022 and other business highlights. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information contained in Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01Financial Statements and Exhibits

 

(d)Exhibits

 

Exhibit No.   Description
99.1   Press Release issued November 3, 2022 regarding financial results and business highlights
     
104  

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 3, 2022 Bicycle Therapeutics plc
   
   
  By: /s/ Lee Kalowski
  Name: Lee Kalowski
  Title: Chief Financial Officer

 

 

 

 EX-99.1 2 tm2229573d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

Bicycle Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

 

-      Continued clinical progress across pipeline including BT5528 end of Phase I dose escalation update; completion of enrollment in BT5528 initial dose expansion cohorts expected in Q4

 

-      BT8009 clinical update remains on-track for Q4

 

-      Received $10 million option fee payment from Genentech this quarter triggered by exclusive strategic collaboration expansion option exercise in Q2

 

-      Cash and cash equivalents of $361.5 million as of September 30, 2022; expected financial runway into 2025

 

CAMBRIDGE, England, & BOSTON, November 3, 2022 – Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the third quarter ended September 30, 2022 and provided recent corporate updates.

 

“We are encouraged by the continued clinical progress across our pipeline,” said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics. “In the third quarter, we announced top-line results from the completed dose escalation portion of the Phase I/II trial in BT5528 and expect to complete enrollment in the initial expansion cohorts this quarter. In addition, clinical development of BT8009 remains on-track and we look forward to providing an update this quarter following completion of the dose escalation portion of the Phase I/II clinical trial. Finally, the dose escalation portion of our Phase I/II trial of BT7480 continues at a healthy pace and we expect to share clinical information in 2023.”

 

“Recently, we added to our balance sheet through Genentech’s second expansion of our immuno-oncology collaboration, resulting in a $10 million payment to us this quarter. We are pleased to have a strong balance sheet which helps support the advancement of our clinical oncology pipeline as well as our earlier discovery and development efforts and which we anticipate provides financial runway into 2025.”

 

Third Quarter 2022 and Recent Highlights

 

·Announced Top-Line Dose Escalation Results of Phase I Trial of BT5528. In September, Bicycle announced top-line results from the Phase I dose escalation portion of its Phase I/II trial of BT5528, a Bicycle® Toxin Conjugate (BTC™) targeting EphA2, in patients with advanced solid tumors. Bicycle observed signs of anti-tumor activity in heavily pre-treated patients with EphA2-postive ovarian and urothelial cancers, demonstrating an overall response rate of 22% (including one complete response) and 67%, respectively. Previously, the company had established a recommended Phase II dose of 6.5mg/m2 every other week. Low, or no, levels of incidence of neutrophil count decrease, peripheral neuropathy, skin rash and eye disorders were reported. Low-grade GI treatment-related events were those most commonly reported amongst the 15 patients at this dose. In addition, and in contrast to the toxicities observed with EphA2 antibody drug conjugates, Bicycle has observed no signs of treatment-related coagulopathy to date in any patient.

 

 

·Enrollment of the Initial Cohorts of The Initial Expansion Cohorts of the BT5528 Phase I/II Trial Remains on Track to Complete This Quarter. The company expects to provide an update on BT5528’s clinical progress in 2023. In June 2022, Bicycle announced the dosing of the first patient in the Phase II dose expansion portion of the Phase I/II trial. The initial dose expansion enrollment plan includes urothelial (n=14) and ovarian (n=14) cancers as well as in a basket cohort of other solid tumors (n=28), including non-small cell lung, triple-negative breast, head and neck, and esophageal cancers.

 

·Announced Publications Highlighting Preclinical Data from BT8009 in Molecular Cancer Therapeutics and the Journal of Medicinal Chemistry. In September, Bicycle announced that an article titled “BT8009: a Nectin-4 targeting Bicycle® Toxin Conjugate for treatment of solid tumors” highlighting preclinical data from BT8009 was published in Molecular Cancer Therapeutics. In October, Bicycle announced an additional publication highlighting preclinical BT8009 data in the Journal of Medicinal Chemistry, titled “Discovery of BT8009: a Nectin-4 Targeting Bicycle® Toxin Conjugate for the Treatment of Cancer.” Both articles are available at the publications section of the Bicycle website via this link.

 

·Announced Expansion of Genentech Immuno-Oncology Collaboration. In July 2022, Bicycle announced that Genentech exercised an option to initiate a new program, expanding the exclusive strategic collaboration agreement with Bicycle to discover, develop and commercialize novel Bicycle®-based immuno-oncology therapies. This expansion represented the second option exercised by Genentech under the terms of the original February 2020 agreement and triggered a $10 million payment to Bicycle, which was received in the third quarter of 2022.

 

Financial Results

 

·Cash and cash equivalents were $361.5 million as of September 30, 2022, compared to $438.7 million as of December 31, 2021. The decrease in cash is primarily due to cash used in operating activities.

 

·Research and development expenses were $22.8 million for the three months ended September 30, 2022, compared to $10.5 million for the three months ended September 30, 2021. The increase in expense of $12.2 million for the three months ended September 30, 2022 as compared to the same period in the prior year was primarily due to increased clinical program expenses for BT5528 and BT8009, Bicycle TICA program development expenses, and other discovery and platform related expenses, as well as increased personnel-related expenses, including $1.4 million of incremental non-cash share-based compensation expenses.

 

·General and administrative expenses were $10.0 million for the three months ended September 30, 2022, compared to $8.1 million for the three months ended September 30, 2021. The increase of $1.9 million for the three months ended September 30, 2022 as compared to the same period in the prior year was primarily due to an increase in personnel-related costs, including $1.3 million of incremental non-cash share-based compensation expense.

 

 

·Net loss was $28.3 million, or $(0.96) basic and diluted net loss per share, for the three months ended September 30, 2022, compared to net loss of $14.7 million, or $(0.59) basic and diluted net loss per share, for the three months ended September 30, 2021.

 

About Bicycle Therapeutics

 

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC®) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICA® targeting Nectin-4 and agonizing CD137, in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, MA. For more information, visit bicycletherapeutics.com.

 

Forward Looking Statements

 

This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding Bicycle’s anticipated advancement of its product candidates, including BT5528, BT8009 and BT7480; the anticipated dosing in and progression of Bicycle’s clinical trials; the availability of and timing of announcement of data from clinical trials; the therapeutic potential for Bicycles in oncology and other applications; Bicycle’s plans to expand its discovery efforts and early development pipeline; and Bicycle’s expected financial runway. Bicycle may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: risks to clinical trial site initiation, patient enrollment and follow-up, as well as to Bicycle’s abilities to meet other anticipated deadlines and milestones, presented by the ongoing COVID-19 pandemic; uncertainties inherent in the initiation and completion of clinical trials and clinical development of Bicycle’s product candidates; the risk that Bicycle may not realize the intended benefits of its technology; availability and timing of results from clinical trials; whether the outcomes of preclinical studies will be predictive of clinical trial results; whether initial or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; the risk that trials may be delayed and may not have satisfactory outcomes; potential adverse effects arising from the testing or use of Bicycle’s product candidates; the risk that Bicycle’s projections regarding its expected financial runway are inaccurate or that its conduct of its business requires more cash than anticipated; and other important factors, any of which could cause Bicycle’s actual results to differ from those contained in the forward-looking statements, are described in greater detail in the section entitled “Risk Factors” in Bicycle’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 4, 2022, as well as in other filings Bicycle may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Bicycle expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

 

 

Bicycle Therapeutics plc

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share data)

(Unaudited)

 

   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2022   2021   2022   2021 
Collaboration revenues  $3,040   $4,333   $11,278   $7,926 
Operating expenses:                    
Research and development   22,752    10,513    56,890    31,924 
General and administrative   10,047    8,114    38,830    23,596 
Total operating expenses   32,799    18,627    95,720    55,520 
Loss from operations   (29,759)   (14,294)   (84,442)   (47,594)
Other income (expense):                    
Interest income   1,991    24    3,117    61 
Interest expense   (817)   (823)   (2,518)   (2,164)
Total other income (expense), net   1,174    (799)   599    (2,103)
Net loss before income tax provision   (28,585)   (15,093)   (83,843)   (49,697)
Benefit from income taxes   (238)   (415)   (1,104)   (915)
Net loss  $(28,347)  $(14,678)  $(82,739)  $(48,782)
Net loss per share, basic and diluted  $(0.96)  $(0.59)  $(2.79)  $(2.06)
Weighted average ordinary shares outstanding, basic and diluted   29,676,021    25,039,990    29,643,502    23,719,124 

 

Balance Sheets Data

(In thousands)

(Unaudited)

 

   September 30,   December 31, 
   2022   2021 
Cash and cash equivalents  $361,469   $438,680 
Working capital   339,733    422,317 
Total assets   417,148    479,792 
Total shareholders’ equity   289,474    346,254 

 

Investors:

David Borah, CFA

VP, Capital Markets & Investor Relations

david.borah@bicycletx.com

617-203-8300

 

Media:

Argot Partners

Sarah Sutton

bicycle@argotpartners.com

212-600-1902

 

 

 EX-101.SCH 3 bcyc-20221103.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 bcyc-20221103_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 bcyc-20221103_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Common Stock [Member] American Depositary Shares [Member] Statement [Table] Document Information [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] American Depositary Shares EX-101.PRE 6 bcyc-20221103_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 tm2229573d1_ex99-1img001.jpg GRAPHIC begin 644 tm2229573d1_ex99-1img001.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#9^-7Q"\1^ M"]6TJWT2ZCACN('>0/"KY(; ZBO+_P#A>WC[_H)V_P#X"1_X5T_[2O\ R']" M_P"O63_T,5P?PN\'V'C?Q=_9&HSW,,'V=Y=UNRALJ1C[P(QSZ4 :O_"]O'W_ M $$[?_P$C_PJ2'X]^.XG#/>6*KJY[ E0N/K@T 3^!OC_;ZOJ$>G^)[6"P>7"QW<)/ ME;O1@A%? DL;PRO%(I5T8JRGL1U%?6_P1UB;5_AC8 M^>Q:2SD>UW$\E5.5_)6 _"@#QK5OC=XZM-9OK:'48!%%<21H#:QG #$#M7L7 MP8\7ZQXR\+WU]K4Z33PWIA1DC5 %V(<8 ]2:Y:__ &<[2^U&YNSXFF0SRO*5 M^R [=Q)Q]_WKT'X=^!(OA_HMSIT6H->B>X,YD:()CY57&,G^[0!V%%%17%S; MVD1EN9XX8QU>1PH_,T 2T5G0:_HUU+Y5OJ]A-)TVQW*,?R!K1H **,XI,CU% M "T444 %%)D>HI: "BD)"@DD #J36:WB/0TD\M]9TY9,XVFZ0'\LT :=%,BF MBGC$D,B21GHR,"#^(I] 'AGQD^)?B?P=XPMM.T:\BAMGLDF97@1SN+N"B MBK?P5^(?B/QGK>IVVMW<4T4%NLD82%4PQ;'85PW[1G_)0[/_ +!L?_HR2M#] MFO\ Y&76_P#KS3_T.@#Z1HHIKND2%Y'5$49+,< 4 .HK,_X2/0Q)Y?\ ;6G; M_P"[]J3/Y9K11UD0.C!E(R&4Y!H =1110 4444 >=_%GX<+XZT19K/"ZS9@F MV9FPLB]3&>W/8]C[9KR+X&:?>:5\6I[&_MI+:ZALY5DBD7#*_B!4CJ"-W!K'USXK^"]#LI)VUVTNY%4E(+.03,Y[#Y<@?4D"ODF;PUKT M,\D4NC:BLB,58&V?@CKVJM<:3J5I'YESI]W"G]Z2%E'ZB@"*]NGO;ZXNY \ M\K2,!ZL&?$FG>+-!M]7TN0O;S#!5N&C8=58 M=B* /CGQV[#XA>)?F/\ R%;KO_TU:OHC]GPD_#1B23_I\O7Z+7SKX[_Y*'XE M_P"PK=?^C6KZ%^ 4R6WPKGGD.$CO)W8^P52: &?%_P"+/_"*1_V)H,Z'6GP9 MI@Y]*^<9KC7/%>K RO?:KJ$QX'S2NWL!SQ["H=9U2?6]:O=4 MNCF>[G>9_8LPP ?J?84 M?.&I>"/%.D6AN]0\/ZC;VZC+2O;MM7ZG''XUK^"/BAX@\&WUN$O9KG2U<>;9 M2MN4IWVY^Z?3'XYK['=%D1D=0R,,,K#((]#7S]XC_9WO[WQ#>W6BZAI]KITT MF^&"7?NC!Y*\*1@'./;% ';_ !$CLOB)\'[C4=$?[5Y:B\MR@^8%/OKCKNVE MQCUKY7TW4KC2]4M+^WD836TR3(<_Q*01_*OK7X5>"=8\":+>Z7J=[:W4,DXF M@\C=\A(PP.X#T7]:^9/B#X?'ACQWJ^E(I6&.&%3S M/-CG\"+[BT%U%X9U5H2-P86K\CU QDUWW[/\ X2L==\07^K:A L\>F+'Y M,;C*^:Q)#8[X"G\P:^GJ /AG2M>\0>$=19M/O;S3KE&Q)&"5Y]&0\'Z$5]4_ M##XCVOCS10LI6+6;9!]K@ P#VWK_ +)].QX]"<7XI_"%_'&IVNJ:5<6MG>JA MCN6FW8E48VGY0>1R/ICTK+^''P>\1^!_&$&KRZKI\MKY;Q7$41? ='$D@\_4KE6%I;CN1_$WH MH)'UZ#V^4]<\5^(_&%Z#J>H75Z[O^[@!.P$] J#@?@*Z/XTZW+K/Q-U)&;,- MCBTB7T"CYO\ QXM72_ :W\,6-W>Z_KNIZ?;WD#"&SCNKA$*Y&67C/_'J^J=SD9*^XQVK*T9 M1'XAMVTUK3?)=$P_99(W>2'SR&\S8H8 0Y)WELL5Y#<5Y'\"O$4VC?$."P!! MMM44V\H/9@"R'ZY&/^!&OJY((8I'DCBC1Y#EV50"WU/>@"2BBB@#R'XZ>/[S MPQI,.B::'BN]2C8M=*V#'&#@A?\ :/3/8>_3S/\ 9\.?B82?^?&7^:UM_M*_ M\A_0O^O63_T,5Y_\-?&-OX&\5?VO'RXV .6QSS]* /L^D95="CJ M&5A@@C((KQ#_ (:4T?\ Z%^^_P"_R55O_P!I:W$##3_#DIF(^5KBY 4'W '/ MYB@#S#XM:)9:!\2=5L]/5$MF*3+$@P(RZABH'89)X]"*](_9IOY?,\0:>6)A MQ#.HSP&^93^8V_E7B&MZS>^(-:N]6U"0275U(9)"!@>P [ # 'TKZ"_9QT": MST'5-\_!J) MY_@CJL48)D>2Z50/4Q@"O!O'?_)0_$O_ &%;K_T:U?1/[/@S\,V!Z?;I?Y+0 M!\K5]J_#2:.?X9^''C(*BQC0X]5&#^H-?*GQ#\)7'@[QC?:>\+K:M(TEI(1P M\1.1@]\=#[BO1O@[\7;#P_IL?AKQ QAM$=FMKS&5C#')5P.<9)(/OSZT ?1] M%<-K'Q=\%:3ILEVNMV]ZZKE+>T?>[GT]!^.*^6O$_C#4_$OB6^UB2>:#[3)N M6))3B-0,*OX #GO0!]O5\_\ [1OA>1GT_P 40(#&JBTN<=1R2C?JP_*NM^!' MA^_TKP;+J.IF<7&IRB1$F)R(E&$.#ZY8_0BNQ\=Z /$W@?5])VYDF@+1?]=% M^9/_ !X"@#YX^ /B"/2/'S6$\@2'4X#"N3@>:IW)_P"S >[5ROQ+UT>(_B'K M.H(^Z#SS#"<\;$&P$?7&?QKF;:XGL;R*YMY&BN()!)&XX*L#D'\"*M:'I8L\+D>Q5@/Y&O M=J^-?AGX_D^'_B&2\:W:YL;F,17,*G#8!R&7W'/'?)^M?3,'Q5\#3V:W0\26 M2(5W;)&*N/;:1G/X4 =C17RE\7OBUT2::/2['=LE!*&=SC+8Z@#&! MGW]:T/@)H^I:SXT.KW$UTUAIT;'<[L4>5AM"^AP"6_ >M $?[1G_ "4.S_[! ML?\ Z,DK0_9K_P"1EUO_ *\T_P#0ZS_VC/\ DH=G_P!@V/\ ]&25H?LU_P#( MRZW_ ->:?^AT >:_$"*2'XB>(DD!W?VC.>?0N2/T(K5\%_"O6_'>ESW^E7>G MQQP3&%TN)'5@< YP%/'/Z&NA^/WA>32?&PUJ.-OLFJ(&+8X650%9?Q #?B?2 MLOX2?$=? >LS0WR,^DWVT3E!EHF&<.!W')R/\,4 :_\ PSIXP_Y_='_[_P G M_P ;H_X9T\8?\_NC_P#?^3_XW7N8^*?@8VWVC_A)K#9C."YW?]\XW?I7SY\5 M/BK+XTU"&VTH36NEV;,8VWE7G8\;R!T&!P/<_0 '5^$/@7XIT#QAI.K75YI; M06ERDL@BF MM?3= !1110!Y#\8OAKKWCK5=,N=(-H([:!XY//E*');/& :\T_X9[\:_W]+_ M / EO_B:^J:* /E;_AGOQK_?TO\ \"6_^)I\?[/'C1W :;2D'J;AC_)*^IJ* M /#/"G[.UM87\-YXCU)+Y(R&^QP1D1N?1F/)'M@5[?;V\-I;QV]M#'##&H5( MXU"JH'0 #H*DHH ^:_$_P+\7ZOXLUG4[9M.^SWE]/<1;[@AMKN6&1MZX->M_ M"CPEJ7@SP:=*U4P&Y-T\O[ERR[2%QS@>AKN:* .;\:>"M*\QZ$=_P J^?\ 6_V>_%MC._\ 9QQGGL!CCJ17NE% , 445XGKW[0D>B>(=1TH^&FF-E_"\FH^+ M)O$$JK]FTQ"J9[RN"!CZ+N/XBO+==UBY\0:[>ZM>,6GNYFE;)SMR>%'L!@#V M%?5_P8\/C0?AKIY>/9<7V;R7/4[_ +O_ (X%H ] J"]LK;4;*:SO($GMID*2 M12#*LIZ@BIZ* /G;Q5^SI>I%[^*6W8DBUNV*NGL& PP^N/QKBF^"/Q!6 M38-!##/WA>08/_C]?7U% 'S+X>_9V\07LROKM[;Z;;CJD1\Z4^W'RCZY/TKZ M)T+0]/\ #FC6^E:9 L-K N%4=2>[$]R>I-:-% 'BGQ<^%?B+QMXLM]3TEK(6 M\=FD!\^4JVX.YZ8/&&%6_@[\-->\#:SJ5UJ[6ACN+=8T\B4N_@R2L4Y\J4 M#L,_=/UR/I7TM10!\@?\*2^(6_;_ &!^/VR#'_H==3X<_9UURZN4D\07MO8V MH(+QP-YLK>W]T?7)^E?2U% &=H>A:;X;TF'2]*MEM[2$?*J]2>Y)[D^M:-%% M !1110 4444 %%%% !1110 4444 %%%% !1110 5XEKW[/:ZWXAU'5?^$E,/ MVVYDN/+^Q;MFYBV,[QG&:]MHH \#C_9GB$BF3Q2[("-P%C@D?7?7O,4200I# M$H6.-0JJ.@ X I]% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 #?__9 end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover
Nov. 03, 2022
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 03, 2022
Entity File Number 001-38916
Entity Registrant Name Bicycle Therapeutics plc
Entity Central Index Key 0001761612
Entity Tax Identification Number 00-0000000
Entity Incorporation, State or Country Code X0
Entity Address, Address Line One Blocks A & B, Portway Building
Entity Address, Address Line Two Granta Park Great Abington
Entity Address, City or Town Cambridge
Entity Address, Country GB
Entity Address, Postal Zip Code CB21 6GS
City Area Code +44
Local Phone Number 1223 261503
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock [Member]  
Document Information [Line Items]  
Title of 12(b) Security Ordinary shares, nominal value £0.01 per share
No Trading Symbol Flag true
Security Exchange Name NASDAQ
American Depositary Shares [Member]  
Document Information [Line Items]  
Title of 12(b) Security American Depositary Shares, each representing one ordinary share, nominal value £0.01 per share
Trading Symbol BCYC
Security Exchange Name NASDAQ
XML 9 tm2229573d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001761612 2022-11-03 2022-11-03 0001761612 us-gaap:CommonStockMember 2022-11-03 2022-11-03 0001761612 bcyc:AmericanDepositarySharesMember 2022-11-03 2022-11-03 iso4217:USD shares iso4217:USD shares 0001761612 false 00-0000000 true 8-K 2022-11-03 Bicycle Therapeutics plc X0 001-38916 Blocks A & B, Portway Building Granta Park Great Abington Cambridge GB CB21 6GS +44 1223 261503 false false false false Ordinary shares, nominal value £0.01 per share NASDAQ American Depositary Shares, each representing one ordinary share, nominal value £0.01 per share BCYC NASDAQ false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 3 24 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://bicycletherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2229573d1_8k.htm bcyc-20221103.xsd bcyc-20221103_def.xml bcyc-20221103_lab.xml bcyc-20221103_pre.xml tm2229573d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2229573d1_8k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 3, "dts": { "definitionLink": { "local": [ "bcyc-20221103_def.xml" ] }, "inline": { "local": [ "tm2229573d1_8k.htm" ] }, "labelLink": { "local": [ "bcyc-20221103_lab.xml" ] }, "presentationLink": { "local": [ "bcyc-20221103_pre.xml" ] }, "schema": { "local": [ "bcyc-20221103.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 65, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 1, "memberStandard": 1, "nsprefix": "bcyc", "nsuri": "http://bicycletherapeutics.com/20221103", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2229573d1_8k.htm", "contextRef": "From2022-11-03to2022-11-03", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://bicycletherapeutics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2229573d1_8k.htm", "contextRef": "From2022-11-03to2022-11-03", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "bcyc_AmericanDepositarySharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "American Depositary Shares", "label": "American Depositary Shares [Member]" } } }, "localname": "AmericanDepositarySharesMember", "nsuri": "http://bicycletherapeutics.com/20221103", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 16 0001104659-22-114205-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-114205-xbrl.zip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